These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 9568680)

  • 1. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
    Spiegelman BM
    Diabetes; 1998 Apr; 47(4):507-14. PubMed ID: 9568680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).
    Lehmann JM; Moore LB; Smith-Oliver TA; Wilkison WO; Willson TM; Kliewer SA
    J Biol Chem; 1995 Jun; 270(22):12953-6. PubMed ID: 7768881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
    Vázquez M; Silvestre JS; Prous JR
    Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):515-23. PubMed ID: 12500431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel insulin sensitizers: pharmacogenomic aspects.
    Otto C; Lehrke M; Göke B
    Pharmacogenomics; 2002 Jan; 3(1):99-116. PubMed ID: 11966407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic and additional vascular effects of thiazolidinediones.
    Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
    Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice.
    Fukui Y; Masui S; Osada S; Umesono K; Motojima K
    Diabetes; 2000 May; 49(5):759-67. PubMed ID: 10905484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism.
    Rangwala SM; Lazar MA
    Trends Pharmacol Sci; 2004 Jun; 25(6):331-6. PubMed ID: 15165749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A role of the PPAR gamma activation in insulin resistance].
    Yoshimasa Y
    Nihon Rinsho; 2001 Nov; 59(11):2173-8. PubMed ID: 11712403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP.
    Mizukami J; Taniguchi T
    Biochem Biophys Res Commun; 1997 Nov; 240(1):61-4. PubMed ID: 9367882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor gamma: A key regulator of adipogenesis and systemic insulin sensitivity.
    Spiegelman BM
    Eur J Med Res; 1997 Nov; 2(11):457-64. PubMed ID: 9385114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adipocyte differentiation and nuclear receptor].
    Hirose T; Kurebayashi S
    Nihon Rinsho; 1997 Jun; 55(6):1596-604. PubMed ID: 9200953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma.
    Iwata M; Haruta T; Usui I; Takata Y; Takano A; Uno T; Kawahara J; Ueno E; Sasaoka T; Ishibashi O; Kobayashi M
    Diabetes; 2001 May; 50(5):1083-92. PubMed ID: 11334412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
    Sugiyama Y
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():416-21. PubMed ID: 12387027
    [No Abstract]   [Full Text] [Related]  

  • 14. [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
    Sugiyama Y; Murase K; Ikeda H
    Nihon Rinsho; 2000 Feb; 58(2):370-5. PubMed ID: 10707560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms by which PPAR gamma modulators regulate insulin sensitivity].
    Yamauchi T; Kadowaki T
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():578-87. PubMed ID: 12387054
    [No Abstract]   [Full Text] [Related]  

  • 16. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity.
    Rieusset J; Touri F; Michalik L; Escher P; Desvergne B; Niesor E; Wahli W
    Mol Endocrinol; 2002 Nov; 16(11):2628-44. PubMed ID: 12403851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interdomain communication regulating ligand binding by PPAR-gamma.
    Shao D; Rangwala SM; Bailey ST; Krakow SL; Reginato MJ; Lazar MA
    Nature; 1998 Nov; 396(6709):377-80. PubMed ID: 9845075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR gamma: an essential role in metabolic control.
    Fajas L; Debril MB; Auwerx J
    Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):64-9. PubMed ID: 11383325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?
    Larsen TM; Toubro S; Astrup A
    Int J Obes Relat Metab Disord; 2003 Feb; 27(2):147-61. PubMed ID: 12586994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [PPAR gamma: a major nuclear receptor in adipogenesis].
    Gervois P; Fruchart JC
    Med Sci (Paris); 2003 Jan; 19(1):20-2. PubMed ID: 12836187
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.